Biotech leads the charge with 9 stocks (ANNX, CLLS, KLRS, PRME, SION, CNTX, OVID, RLMD, SPRB) recently rated strong buy. Large-cap retailers COST and ORLY also saw upgrades to Strong Buy on Tuesday and Sunday, respectively. Average target prices suggest continued upside momentum. However, financial and select biotech downgrades, including FHN and DVAX, warrant caution in certain growth areas.
“`
Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.